Related Experiment Video
Updated: Sep 19, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetic Lethality as Emerging Treatment for Cancer: An Example by Using the Werner Syndrome Helicase (WRN)
1Independent Consultant, 1383 Jasper Drive, Ambler, Pennsylvania 19002, United States.
Abstract:
The invention in this patent application relates to chemical compounds represented herein generally by Formula 1a. These compounds are inhibitors of the Werner Syndrome ATP-dependent helicase (WRN) enzyme activity. The compounds of the invention may particularly be useful in treating cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair (dMMR) system.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Replicative Cell Senescence
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Homologous Recombination

